A possible explanation for the improved RFS in patients with higher proportion of M2 TAMs in our study is that M2 TAMs are associated with high PD-L1 expression on tumor cells and immune cells, and may have contributed to improved efficacy of PD-L1 inhibitor (42). The gene discussed is CD274; the disease is neoplasm.